AstraZeneca PLC





Market Closed - London S.E. 11:35:22 2024-05-24 am EDT 5-day change 1st Jan Change
12,296 GBX -0.87% Intraday chart for AstraZeneca PLC +1.54% +16.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Innate Pharma: five abstracts selected for ASCO CF
Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial MT
AstraZeneca: licensing agreement signed with Nona Biosciences CF
HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16% MT
Behind the numbers: AstraZeneca aims for sales of $80 billion by 2030 Our Logo
Stifel Raises AstraZeneca PT, Maintains Buy Rating MT
AstraZeneca PLC Furthers Ambition to Transform Outcomes in Early Lung Cancer and Redefine Metastatic Breast Cancer Treatment at ASCO 2024 CI
ASTRAZENECA : Oddo BHF raises its target slightly CF
Barclays cuts NextEnergy but lifts JLEN AN
ASTRAZENECA : Gets a Neutral rating from Deutsche Bank ZD
AstraZeneca to present new oncology data CF
ASTRAZENECA : JP Morgan keeps its Buy rating ZD
US Equity Indexes Little Changed as Fed Officials Pepper Views on Policy Path, Investors Brace for Nvdia's Earnings MT
US Equity Indexes Slightly Higher in Midday Trading MT
European Equities Close Lower in Tuesday Trading; AstraZeneca Targets $80 Billion in Revenue by 2030 MT
London dips as eyes turn to UK inflation reading AN
London's FTSE 100 closes at one week-low ahead of CPI data RE
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET DJ
AstraZeneca says building China supply chain amid US-China tensions RE
AstraZeneca aims for $80 bln in total revenue by 2030 RE
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET DJ
Stocks fall but pound up as IMF ups UK forecast AN
Stocks fall but pound up as IMF ups UK forecast AN
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
156.7 USD
Average target price
170.1 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca's Board Increases 2024 Dividend by 7% to $3.10 per Share